Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

The news came as Roche recorded a 10% increase in first-quarter revenues to CHF 16.4 billion ($17.2 billion), on strong US demand for rapid COVID-19 antigen tests, as well as the performances of ...

Whether it’s a budget, a new hire or a family vacation, George A. Roche, the newly elected chairman and president of T. Rowe Price Associates Inc., isn’t satisfied until he has painstakingly ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics , the Wall Street Journal reported on Wednesday, citing ...

After hours: March 13 at 7:52:56 PM EDT Loading Chart for TOPS ...

Here at Startup Savant, we love startup culture. That’s why we identified a variety of companies at all stages — from seed funding to series B funding and beyond. These are some of the top startups in ...

Download 'It Isn't Perfect But It Might Be (from 'Bridget Jones: Mad About the Boy' Original Motion Picture Soundtrack)' on iTunes ...